The most substantial of the trials, which was conducted by the National Institute of Allergy and Infectious Diseases, examined recovery times for hospitalized COVID-19 patients when provided either remdesivir or a placebo. The typical healing time for clients in the remdesivir group was 10 days, compared to 15 days for the placebo group.
The drug, which the FDA states can only be administered to patients who are hospitalized and weigh 88 pounds or more, is the first to get approval from the firm to treat COVID-19.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.
The decision was based upon the FDAs analysis of information from 3 randomized, controlled scientific trials carried out on hospitalized patients with moderate to severe COVID-19..
More posts on drug store:12 drugs being evaluated as COVID-19 treatmentsDrug shortages expected to aggravate as COVID-19 hospitalizations surgeA breakdown of the 4 COVID-19 vaccine trials in late-stage screening.
The FDA on Oct. 22 approved approval to remdesivir, which Gilead sells under the brand name Veklury, as a COVID-19 treatment for hospitalized clients aged 12 years and older.
” Todays approval is supported by data from multiple medical trials that the firm has carefully evaluated and represents an important scientific milestone in the COVID-19 pandemic,” FDA Commissioner Stephen Hahn, MD, said in a declaration..
Katie Adams –
Thursday, October 22nd, 2020